Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5243
Gene Symbol: ABCB1
ABCB1
0.020 GeneticVariation phenotype BEFREE CYP2D6 and ABCB1 polymorphisms were associated with the incidence of dizziness and prolonged corrected QT interval, respectively. 29061081 2017
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.020 GeneticVariation phenotype BEFREE CYP2D6 and ABCB1 polymorphisms were associated with the incidence of dizziness and prolonged corrected QT interval, respectively. 29061081 2017
Entrez Id: 5243
Gene Symbol: ABCB1
ABCB1
0.020 GeneticVariation phenotype BEFREE i) In the experimental mouse model, we observed that brain concentrations of cabergoline were tenfold higher in the mutant mice compared with their wild-type littermates, implying that cabergoline is indeed a substrate of the transporter P-gp at the blood-brain barrier level. ii) In the human study, we observed significant negative associations under cabergoline for the C-carriers and heterozygous CT individuals of SNP rs1045642 with two central side effects (frequency of fatigue and sleep disorders) and for the G-carriers of SNP rs2032582 with the enhancement of dizziness. 22672924 2012
Entrez Id: 1565
Gene Symbol: CYP2D6
CYP2D6
0.020 GeneticVariation phenotype BEFREE Conventional dosage regimen led to toxic plasma concentration of NT and adverse effects such as dry mouth, constipation, and dizziness in this case with genotype CYP2D6*5/*10B. 15483356 2004
Entrez Id: 3479
Gene Symbol: IGF1
IGF1
0.010 AlteredExpression phenotype BEFREE S-Ca (HR 1.21 (1.02; 1.44) p = 0.028) also predicted future fractures, whereas PTH, IGF-1, 25(OH) vitamin D, hormone replacement therapy, smoking, degree of physical activity, impaired vision and dizziness did not. 31720709 2020
Entrez Id: 1523
Gene Symbol: CUX1
CUX1
0.010 Biomarker phenotype BEFREE Patients were assessed with objective outcome measures (sensorial organization test and limits of stability-LOS-of CDP, modified timed up and go test-TUG-and number of falls) and with subjective outcome measures (dizziness handicap inventory and Short falls efficacy scale-international-Short FES-I) during a 12-month follow-up period. 30977081 2020
Entrez Id: 4878
Gene Symbol: NPPA
NPPA
0.010 Biomarker phenotype BEFREE Patients were assessed with objective outcome measures (sensorial organization test and limits of stability-LOS-of CDP, modified timed up and go test-TUG-and number of falls) and with subjective outcome measures (dizziness handicap inventory and Short falls efficacy scale-international-Short FES-I) during a 12-month follow-up period. 30977081 2020
Entrez Id: 2740
Gene Symbol: GLP1R
GLP1R
0.010 Biomarker phenotype BEFREE Ranking probability analysis indicated that GLP-1 RAs may have the greatest risk of both dizziness and headache among the nine treatments (22.5% and 23.4%, respectively), whereas DPP-4Is were in the middle (46.2% and 45.0%, respectively). 31788342 2019
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.010 Biomarker phenotype BEFREE Ranking probability analysis indicated that GLP-1 RAs may have the greatest risk of both dizziness and headache among the nine treatments (22.5% and 23.4%, respectively), whereas DPP-4Is were in the middle (46.2% and 45.0%, respectively). 31788342 2019
Entrez Id: 80025
Gene Symbol: PANK2
PANK2
0.010 AlteredExpression phenotype BEFREE For HSS, the active group showed reduced hangover symptoms while there were higher levels of nausea, headache, anorexia, tremulousness, diarrhoea and dizziness in the placebo group (p < 0.05) at hour 10 post-intoxication. 30922154 2019
Entrez Id: 6448
Gene Symbol: SGSH
SGSH
0.010 AlteredExpression phenotype BEFREE For HSS, the active group showed reduced hangover symptoms while there were higher levels of nausea, headache, anorexia, tremulousness, diarrhoea and dizziness in the placebo group (p < 0.05) at hour 10 post-intoxication. 30922154 2019
Entrez Id: 9043
Gene Symbol: SPAG9
SPAG9
0.010 AlteredExpression phenotype BEFREE For HSS, the active group showed reduced hangover symptoms while there were higher levels of nausea, headache, anorexia, tremulousness, diarrhoea and dizziness in the placebo group (p < 0.05) at hour 10 post-intoxication. 30922154 2019
Entrez Id: 64374
Gene Symbol: SIL1
SIL1
0.010 Biomarker phenotype BEFREE To study PNS vulnerability in MSS, intramuscular nerves fibres from MSS patients and from SIL1-deficient mice (woozy) as well as sciatic nerves and neuromuscular junctions (NMJ) from these mice have been investigated via transmission electron microscopic and immunofluorescence studies accompanied by transcript studies and unbiased proteomic profiling. 30468864 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.010 Biomarker phenotype BEFREE Accordingly, DB is often underdiagnosed or misdiagnosed, given the similarity of its associated symptoms (dyspnea, tachycardia, and dizziness) to those of other common cardiopulmonary diseases such as COPD and asthma. 30758427 2019
Entrez Id: 9311
Gene Symbol: ASIC3
ASIC3
0.010 GeneticVariation phenotype BEFREE However, whether the genetic variants of <i>ASIC3</i> are associated with people who suffer dizziness and balance impairment after mTBI remained unknown. 30804886 2019
Entrez Id: 3094
Gene Symbol: HINT1
HINT1
0.010 Biomarker phenotype BEFREE We included patients 18 years of age or older, visiting the adult ED of a French university hospital for a new episode of dizziness evolving for less than 72 h. All patients underwent standardized physical examination (HINT [Head Impulse test, Nystagmus, test of skew deviation] maneuvers), copeptin and S-100b protein (PS100) measurement and injected brain imaging. 31387626 2019
Entrez Id: 2242
Gene Symbol: FES
FES
0.010 Biomarker phenotype BEFREE A sample of 662 79-year-olds (404 women, 258 men) were investigated with questions regarding dizziness, previous falls and falls efficacy [estimated according to the falls efficacy scale Swedish version (FES (S))]. 31489596 2019
Entrez Id: 7170
Gene Symbol: TPM3
TPM3
0.010 Biomarker phenotype BEFREE While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic. 31738426 2019
Entrez Id: 8864
Gene Symbol: PER2
PER2
0.010 Biomarker phenotype BEFREE This was an interventional study using medical records to collect data for acute dizziness presentations before (period 1, 2012-2014) and after (period 2, 2016-2017) the implementation of a management algorithm. 31098875 2019
Entrez Id: 3769
Gene Symbol: KCNJ13
KCNJ13
0.010 Biomarker phenotype BEFREE Finally, we propose that SVD-mediated dysregulation of cerebral blood pressure is linked to dizziness during standing and walking in elderly patients with "unexplained" dizziness. 31239134 2019
Entrez Id: 1803
Gene Symbol: DPP4
DPP4
0.010 Biomarker phenotype BEFREE As a new class of antidiabetic drug, incretin-based therapies, which include dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have raised concerns about symptoms of withdrawal in patients with type 2 diabetes mellitus (T2DM), such as dizziness and headache. 31788342 2019
Entrez Id: 83932
Gene Symbol: SPRTN
SPRTN
0.010 Biomarker phenotype BEFREE Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials. 31152441 2019
Entrez Id: 2697
Gene Symbol: GJA1
GJA1
0.010 AlteredExpression phenotype BEFREE For HSS, the active group showed reduced hangover symptoms while there were higher levels of nausea, headache, anorexia, tremulousness, diarrhoea and dizziness in the placebo group (p < 0.05) at hour 10 post-intoxication. 30922154 2019
Entrez Id: 100125288
Gene Symbol: ZGLP1
ZGLP1
0.010 Biomarker phenotype BEFREE Ranking probability analysis indicated that GLP-1 RAs may have the greatest risk of both dizziness and headache among the nine treatments (22.5% and 23.4%, respectively), whereas DPP-4Is were in the middle (46.2% and 45.0%, respectively). 31788342 2019
Entrez Id: 2670
Gene Symbol: GFAP
GFAP
0.010 Biomarker phenotype BEFREE Dizziness was associated with reaction time decrements, GFAP or NfL suppression, as well as Aβ peptide elevation. 31408492 2019